10th Oct 2013 15:22
10 October 2013
Source BioScience plc
Director's Exercise of Share Options
Source BioScience plc (LSE: SBS) ("Source BioScience" or "the Company") announces that Chairman,Laurie Turnbull, has exercised 400,000 share options under the Company's 1999 Unapproved Share Option Scheme. After the exercise of the Share Options, Mr Turnbull will hold 4,850,000 Ordinary 2p shares (1.5%) in the Company.
Interest after purchase | |||||
Director/PDMR | Title | Exercise price per share (p) | Number of Ordinary Shares acquired on 9 October 2013 | Number of Ordinary Shares | % of total issued share capital |
LaurieTurnbull
|
Non-Executive Chairman |
4.63 |
400,000 |
4,850,000 |
1.5 |
An application has been made for the Ordinary Shares to be admitted to the Official List of the UK Listing Authority and to trading on the Main Market of the London Stock Exchange. Admission of the new Ordinary Shares will be made as soon as practical.
Following the issue and allotment, the Company's issued share capital will comprise 313,273,965 ordinary shares of 2 pence each, which figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, Source BioScience plc under the FSA's Disclosure and Transparency Rules. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.
Enquiries
Source BioScience plc
Dr Nick Ash, CEO
Tel: +44 (0) 115 973 9010
Email: [email protected]
www.sourcebioscience.com
For investor and media enquiries:
N+1 Singer (Financial Advisor, Sponsor and Broker to Source BioScience)
Aubrey Powell/ Joseph Stroud/ Laura White
Tel: +44 (0)20 7496 3000
www.n1singer.com
College Hill (PR Agency to Source BioScience)
Melanie Toyne-Sewell/ Claire Dickinson
Tel: +44 (0)20 7457 2020
Email: [email protected]
About Source BioScience:
Source BioScience plc (LSE: SBS) is an international diagnostics and genetic analysis business serving the healthcare and research markets. The LifeSciences division provides core laboratory research support from conceptualisation to implementation, calling upon a wide range of innovative technology platforms including an online catalogue of biomolecular tools. Source BioScience is a trusted provider of a complete range of sophisticated microarray, next generation and conventional sequencing services. GLP, GCP and CPA accreditations make the sequencing offerings very attractive for applications in regulatory studies or clinical settings. The Healthcare operations provide screening and reference laboratory diagnostic testing for cancer and other diseases in addition to complementary products for serology and diagnostic applications. Source BioScience has its headquarters in Nottingham, UK. For more information, see www.sourcebioscience.com.
Related Shares:
SBS.L